{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:58:15Z","timestamp":1793923095255,"version":"4.8.0"},"reference-count":90,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamadermatol.2022.1624","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T11:32:59Z","timestamp":1653478379000},"page":"933","source":"Crossref","is-referenced-by-count":88,"title":["Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer"],"prefix":"10.1001","volume":"158","author":[{"given":"Maria S.","family":"Asdourian","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Virginia Commonwealth University School of Medicine, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted V.","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"drv220001r1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors.","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"drv220001r2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy.","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"drv220001r3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"drv220001r4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"issue":"6","key":"drv220001r5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bjd.v183.6","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study.","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"drv220001r6","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"drv220001r8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.2018.57.issue-6","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"3","key":"drv220001r9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"drv220001r10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CMAR","article-title":"Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease.","volume":"7","author":"Cavalcante","year":"2015","journal-title":"Cancer Manag Res"},{"key":"drv220001r11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-016-0123-3","article-title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.","volume":"4","author":"Beck","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"6","key":"drv220001r12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy.","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"4","key":"drv220001r13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajd.12484","article-title":"Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab.","volume":"57","author":"Lomax","year":"2016","journal-title":"Australas J Dermatol"},{"issue":"9","key":"drv220001r14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cup.2016.43.issue-9","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"4","key":"drv220001r15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"issue":"5","key":"drv220001r16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1.","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"drv220001r17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.2016.43.issue-8","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"10","key":"drv220001r18","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/jde.2017.44.issue-10","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"issue":"3","key":"drv220001r19","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/ajd.2017.58.issue-3","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"8","key":"drv220001r20","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"drv220001r21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jdcr.2017.06.004","article-title":"Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy.","volume":"3","author":"Hirotsu","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"8","key":"drv220001r22","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology.","volume":"31","author":"Bandino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"drv220001r23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid.","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"drv220001r24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ced.2017.42.issue-3","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"drv220001r25","first-page":"301","article-title":"Management of dermatological adverse events during nivolumab treatment.","volume":"13","author":"Slowinska","year":"2017","journal-title":"Oncol Clin Pract"},{"issue":"2","key":"drv220001r26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1684\/ejd.2016.2959","article-title":"Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab.","volume":"27","author":"Russo","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"10","key":"drv220001r27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern.","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"drv220001r28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/CJI.0000000000000210","article-title":"Bullous Pemphigoid\u2013like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature.","volume":"41","author":"Anastasopoulou","year":"2018","journal-title":"J Immunother"},{"issue":"1","key":"drv220001r29","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1111\/jde.2018.45.issue-1","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.","volume":"45","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol"},{"key":"drv220001r30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2018.08.022","article-title":"Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.","volume":"103","author":"Panariello","year":"2018","journal-title":"Eur J Cancer"},{"issue":"10","key":"drv220001r31","doi-asserted-by":"publisher","DOI":"10.1177\/2054270418793029","article-title":"Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.","volume":"9","author":"Hanley","year":"2018","journal-title":"JRSM Open"},{"issue":"10","key":"drv220001r32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management.","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"drv220001r33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ddg.13411","article-title":"Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.","volume":"16","author":"Amber","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"drv220001r34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer.","volume":"41","author":"Garje","year":"2018","journal-title":"J Immunother"},{"issue":"11","key":"drv220001r35","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ijd.2018.57.issue-11","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"issue":"1","key":"drv220001r36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000487127","article-title":"Intensity-modulated radiotherapy triggers onset of bullous pemphigoid in a patient with advanced melanoma treated with nivolumab.","volume":"11","author":"Tanita","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"3","key":"drv220001r37","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/jdv.2018.32.issue-3","article-title":"Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy.","volume":"32","author":"Le Naour","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"drv220001r38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000489661","article-title":"Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports.","volume":"10","author":"Thomsen","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"drv220001r39","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"drv220001r40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"drv220001r41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.25251\/skin.2.3.5","article-title":"Development of bullous pemphigoid while receiving PD-1 checkpoint inhibitor nivolumab.","volume":"2","author":"Nahmias","year":"2018","journal-title":"Skin (Los Angeles)"},{"issue":"7","key":"drv220001r42","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1111\/jde.2019.46.issue-7","article-title":"Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.","volume":"46","author":"Adachi","year":"2019","journal-title":"J Dermatol"},{"issue":"5","key":"drv220001r43","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v32.5","article-title":"Bullous pemphigoid in a patient treated with nivolumab.","volume":"32","author":"Cuenca-Barrales","year":"2019","journal-title":"Dermatol Ther"},{"issue":"10","key":"drv220001r44","doi-asserted-by":"publisher","DOI":"10.5070\/D32510045817","article-title":"Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"issue":"4","key":"drv220001r45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12924","article-title":"A case of atezolizumab-induced photodistributed bullous pemphigoid.","volume":"32","author":"Leavitt","year":"2019","journal-title":"Dermatol Ther"},{"key":"drv220001r46","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3389\/fimmu.2019.01934","article-title":"Checkpoint inhibition may trigger the rare variant of anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid.","volume":"10","author":"Sadik","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"drv220001r47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ccr3.2019.7.issue-4","article-title":"Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient.","volume":"7","author":"Honigman","year":"2019","journal-title":"Clin Case Rep"},{"issue":"3","key":"drv220001r48","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1111\/ajd.v60.3","article-title":"Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.","volume":"60","author":"Grimaux","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"4","key":"drv220001r49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jdcr.2019.02.008","article-title":"Pembrolizumab-induced bullous pemphigoid.","volume":"5","author":"Sun","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"14","key":"drv220001r50","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jama.2020.10159","article-title":"Pruritus and tense bullae after discontinuation of pembrolizumab in a patient with renal cell carcinoma.","volume":"324","author":"Bieber","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"drv220001r51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jdcr.2020.01.008","article-title":"Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma.","volume":"6","author":"Virgen","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"drv220001r52","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Nivolumab-associated pemphigoid-like blistering dermatosis after sun exposure.","volume":"33","author":"Kluger","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"drv220001r53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2169\/internalmedicine.3264-19","article-title":"Bullous pemphigoid in a patient treated with pembrolizumab.","volume":"59","author":"Hara","year":"2020","journal-title":"Intern Med"},{"issue":"3","key":"drv220001r54","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/ijd.IJD_321_18","article-title":"Nivolumab-induced bullous pemphigoid managed without drug withdrawal.","volume":"65","author":"Munera-Campos","year":"2020","journal-title":"Indian J Dermatol"},{"issue":"5","key":"drv220001r55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jdcr.2020.03.003","article-title":"Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.","volume":"6","author":"Qiu","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"drv220001r56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/ijd.v59.6","article-title":"Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer.","volume":"59","author":"Lee","year":"2020","journal-title":"Int J Dermatol"},{"key":"drv220001r57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2020.07.027","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid: towards a new class of drug-drug interaction?","volume":"138","author":"Pujalte-Martin","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"drv220001r58","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/jde.v47.1","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: a case report.","volume":"47","author":"Muto","year":"2020","journal-title":"J Dermatol"},{"issue":"11","key":"drv220001r59","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1200\/JOP.19.00751","article-title":"Pembrolizumab-induced bullous pemphigoid treated with rituximab.","volume":"16","author":"Sharma","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"drv220001r60","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijwd.2020.09.001","article-title":"Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab.","volume":"6","author":"Maya","year":"2020","journal-title":"Int J Womens Dermatol"},{"issue":"8","key":"drv220001r61","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/cup.v47.8","article-title":"Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series.","volume":"47","author":"Morris","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"2","key":"drv220001r62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/ddg.v18.2","article-title":"Unusual flaccid blistering with mucosal involvement upon immune checkpoint inhibition.","volume":"18","author":"Niebel","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"drv220001r63","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis","article-title":"Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.","volume":"105","author":"Schwartzman","year":"2020","journal-title":"Cutis"},{"key":"drv220001r64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.20517\/2394-4722.2020.77","article-title":"Nivolumab-induced severe bullous pemphigoid in a patient with renal cancer: a case report and literature review.","volume":"6","author":"Wu","year":"2020","journal-title":"J Cancer Metastasis Treat"},{"key":"drv220001r65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2020.100031","article-title":"Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid.","volume":"2","author":"Mihailescu","year":"2020","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"drv220001r66","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/ijd.v61.4","article-title":"Bullous pemphigoid probably associated with pembrolizumab: a case of delayed toxicity.","volume":"61","author":"Correia","year":"2022","journal-title":"Int J Dermatol"},{"issue":"1","key":"drv220001r67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1159\/000514144","article-title":"Refractory bullous pemphigoid in a patient with metastatic lung adenocarcinoma treated with pembrolizumab.","volume":"14","author":"Cardona","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"6","key":"drv220001r68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/ijd.v60.6","article-title":"Pembrolizumab-induced reactivation of bullous pemphigoid.","volume":"60","author":"Kaul","year":"2021","journal-title":"Int J Dermatol"},{"issue":"3","key":"drv220001r69","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12328-021-01396-5","article-title":"Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.","volume":"14","author":"Eguchi","year":"2021","journal-title":"Clin J Gastroenterol"},{"issue":"9","key":"drv220001r70","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1111\/jdv.v35.9","article-title":"Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors.","volume":"35","author":"Povilaityte","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"drv220001r71","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1159\/000514806","article-title":"A late dermatologic presentation of bullous pemphigoid induced by anti\u2013PD-1 therapy and associated with unexplained neurological disorder.","volume":"14","author":"Wang","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"6","key":"drv220001r72","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cia2.12189","article-title":"A case of bullous pemphigoid after a long-term administration of anti-PD-1 antibodies in a patient with non-small-cell lung cancer.","volume":"4","author":"Yokoyama","year":"2021","journal-title":"J Cutan Immunol Allergy"},{"issue":"7","key":"drv220001r73","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16169","article-title":"A rare case of bullous pemphigoid secondary to checkpoint inhibitor immunotherapy: a tense situation.","volume":"13","author":"Wesolow","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"drv220001r74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/jde.v48.3","article-title":"Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.","volume":"48","author":"Sugawara","year":"2021","journal-title":"J Dermatol"},{"key":"drv220001r75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdcr.2021.04.027","article-title":"Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1.","volume":"13","author":"Wiggins","year":"2021","journal-title":"JAAD Case Rep"},{"key":"drv220001r76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers.","volume":"11","author":"Sadik","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"drv220001r77","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid.","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"drv220001r78","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3853","article-title":"Inhibition of transforming growth factor beta and immune checkpoints induces a distinctively distributed, severe bullous pemphigoid.","volume":"101","author":"Choi","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"10088","key":"drv220001r79","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial.","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"drv220001r80","doi-asserted-by":"publisher","first-page":"30048","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes.","volume":"S0190-9622","author":"Nelson","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"drv220001r81","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/jcm10040728","article-title":"The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes.","volume":"10","author":"Hashimoto","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"drv220001r82","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1111\/jdv.v35.8","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study.","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"drv220001r83","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40261-021-01042-5","article-title":"Spontaneous and immune checkpoint inhibitor-induced autoimmune diseases: analysis of temporal information by using the Japanese adverse drug event report database.","volume":"41","author":"Ogawa","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"6","key":"drv220001r84","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"drv220001r85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations.","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"drv220001r86","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36823","article-title":"Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma.","volume":"4","author":"Jang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"drv220001r87","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy.","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"drv220001r88","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature.","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"drv220001r89","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"drv220001r90","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid.","volume":"155","author":"Kridin","year":"2019","journal-title":"JAMA Dermatol"},{"key":"drv220001r7","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Accessed April 25, 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2792449\/jamadermatology_asdourian_2022_rv_220001_1659459473.10861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:07:56Z","timestamp":1660907276000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2792449"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1624","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}